Year All2024202320222021 Sep 05, 2024 Lexeo Therapeutics to Participate in Upcoming Investor Conferences Aug 12, 2024 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights Jul 15, 2024 Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Jul 11, 2024 Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024 Jul 08, 2024 Lexeo Therapeutics Appoints Tim Van Hauwermeiren to its Board of Directors May 09, 2024 Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights May 07, 2024 Lexeo Therapeutics to Participate in Upcoming Investor Conferences Apr 22, 2024 Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy Apr 16, 2024 Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy Mar 13, 2024 Lexeo Therapeutics Announces Closing of Oversubscribed $95.0 Million Equity Financing
Aug 12, 2024 Lexeo Therapeutics Reports Second Quarter 2024 Financial Results and Operational Highlights
Jul 15, 2024 Lexeo Therapeutics Announces Positive Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Jul 11, 2024 Lexeo Therapeutics Announces Investor Webcast to Report Interim Phase 1/2 Clinical Data of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy on Monday, July 15, 2024
May 09, 2024 Lexeo Therapeutics Reports First Quarter 2024 Financial Results and Operational Highlights
Apr 22, 2024 Lexeo Therapeutics Announces License Agreement to Accelerate Development of LX2006 for the Treatment of Friedreich Ataxia Cardiomyopathy
Apr 16, 2024 Lexeo Therapeutics Granted FDA Fast Track Designation for LX2006, an AAV-Based Gene Therapy Candidate for the Treatment of Friedreich’s Ataxia Cardiomyopathy